gelmetix

Our Origins

Our technology originated from the University of Manchester and two scientific founders, Professors Tony Freemont and Brian R Saunders. In 2012 the university decided to create a spin-off company, in order to develop the technology into a viable commercial product.

Play Watch Our Video

What We Do

Gelemetix is a diversified therapeutic biomaterials company incorporated in the UK. It has offices in London, Paris and Manchester.

Gelmetix develops multiple grades of polymer gel to provide affordable non-invasive alternatives to surgery. Our goal is to become a diversified solution-platform and to subsequently develop and in-license different families of products. All of these products will be based on four core pillars:

four
ico-what-2

Biomimetic Polymer Gels

The unifying factor behind all of Gelmetix’s products will be polymer gels. These will be nature mimicking, smart materials, which work with the body’s natural tissues.

ico-what-3

Original & Inventive Solutions

Our ‘founding product’, DXM (working name), was born out of academic research with a new biological perspective. Like all our solutions will, it took a paradigm-changing approach. It adopted a novel way of thinking based on a more biological and physio-pathological approach and earlier intervention than usually practiced. All of our products will also employ clever delivery mechanisms.

ico-what-4

Multi-dimensional Benefits

Our goal is for our diversified solutions to provide multiple benefits for patients, healthcare practitioners, healthcare budget holders, national governments, insurance providers, economic drivers (such as employers) and investors.

ico-what-1

Minimally Invasive & Cost Effective

None of our solutions will require a surgical procedure or will have a need for a general anaesthetic. All will be a day-patient treatment, administered through well-known, safe and simple practices, similar to the one used for treatments like discography. This means our solutions will potentially create a reduction in long-term patient care and later surgical intervention costs.

Our Vision & Mission

Our Vision

Transforming individuals’ lives through early-stage, minimally-invasive, effective and affordable solutions to either chronic pain or poor body functioning.

Our Mission

To develop and market a multi-product portfolio of gel-based, therapeutic biomaterial medical devices. Each product will be a superior demonstration of the novel application of innovative science and technology.

Our Values

Ambitious

Our quest is to find effective solutions to conditions that prevail around the world; to bring real and tangible relief to sufferers, in the process transforming their and their families lives. It’s an ambitious goal which we believe will benefit both patients around the world and our business.

Focused

We concentrate on two core areas – pain relief and improved body functioning – and the use of potent biomimetic polymer micro-gels to relieve these conditions.

Open-minded

We aspire to find new solutions to long-standing problems; to look at prevalent and costly current conditions and bring new perspectives to bear. We welcome partnerships and collaborations, which will help us to achieve this goal.

Science-based

All of our products will have a firm foundation in science, in the application of expert, scientific knowledge and the rigour of research.

Management Team

Member

Dr. Philippe Jenny

Chief Executive Officer

Philippe is a medical doctor trained in spine surgery with an impressive career in the development and commercialisation of innovative devices to treat spinal and other conditions. He’s worked specially at Sofamor-Stryker Spine and on numerous other assignments, such as Solvay, Spinplant, Centes and Innospine.

Member

Dr. Sam Bakri

President & Chief Business Officer

Sam is a serial entrepreneur and is notably the co-founder of AIDA Health and co-founder and ex-CEO Kind Consumer. Sam is also an advisor to UKTI and Helios Investment Partners. He studied medicine at the University of London and has an MBA from Harvard Business School where he was a Fulbright Scholar.

Member

Dr. Jane Bramhill

Chief Technology Officer

Jane has a PhD in Polymer Chemistry. Over the past 10 years she has investigated several alternative polymer gels for medical applications. She has a strong experience in translating academic concepts into commercial products.

Member

Prof. David Goldsmith

Chief Medical Officer

David has an extensive experience in conducting clinical studies. He has held various positions at Guy’s and St Thomas’ Hospital, the Royal College of Physicians of Edinburgh and Cardiovascular and Cell Sciences Institute, St George's University of London. He studied medicine at the University of Cambridge. He has published nearly 500 papers, and has a "H" (Hirsch) Index of 57.

Member

Jayne Thorpe

Chief Financial Officer

Jayne is an accountant and has worked in healthcare, finance and M&A consulting for PwC, KPMG and Kurt Salmon. She has an MBA from Oxford and an MSc in Health Economics, Management and Policy from LSE. Jayne has over ten years of experience advising start-up companies.

Member

Tristan Courtial

Head of Strategy

Tristan has over 7 years of experience in strategy and M&A, during which he worked for Strategy& (PwC), and L.E.K consulting. He has a MSc in Engineering from Ecole des Mines de Nantes, and a MSc in Management from Ecole des Mines de Paris and Paris X university.

Board of Directors

Member

Michael Fiore

Chairman

Michael has more than 37 years of experience in the Health Care Services, Technology and Medical Device Industry. He holds an MBA from Harvard University, an MSc in Accounting (NYU) and a BA in Economics and Anthropology (Amherst College). Mike is the Co-Founder and CEO of Vantage Oncology LLC. Mike is also Chairman of California Cryobank and Infusion Express, and serves as a Partner at Linden LLC, a health care private equity firm.

Member

Dr. Philippe Jenny

Chief Executive Officer

Philippe is a medical doctor trained in spine surgery with an impressive career in the development and commercialisation of innovative devices to treat spinal and other conditions. He’s worked specially at Sofamor-Stryker Spine and on numerous other assignments, such as Solvay, Spinplant, Centes and Innospine.

Member

Dr. Sam Bakri

President & Chief Business Officer

Sam is a serial entrepreneur and is notably the co-founder of AIDA Health and co-founder and ex-CEO Kind Consumer. Sam is also an advisor to UKTI and Helios Investment Partners. He studied medicine at the University of London and has an MBA from Harvard Business School where he was a Fulbright Scholar.

Member

Tony Freemont

Co-Founder, Director

Tony is a Professor in Osteoarticular Pathology, Lead Pathologist and Deputy Director at Central Manchester University NHS Trust, NED at Christie NHS Trust, head of the Medical Education and School of Biomedicine at Manchester Medical School. Tony is the inventor of the DXM technology, academic cofounder and former Chairman of Gelmetix (previously Gelexir Healthcare).

Member

Gerard De Geer

Director

Gerard De Geer currently serves as Senior Adviser of IK Investment Partners. He previously spent 9 years with the firm as a Partner in Strategy, Operations and Business Control. Prior to this Gerard spent eight years as a Vice President at A.T. Kearney in Stockholm and spent 12 years working in general management positions in the manufacturing industry. He serves as the Chairman and board member of several companies and is a seasoned investor.

Member

Navin Khattar

Director

Navin Khattar is the Executive director with a global investment company. He is also Non Executive Director of a global education service provider listed on AIM. Navin is a qualified solicitor of the Law Society of England & Wales and previously practised within the City of London, specialising in corporate finance. He holds an LLB (Hons) degree from the University of Bristol.